跳至主要内容
临床试验/NCT02394249
NCT02394249已完成不适用

SIT LESS 3: The Effect of Low Intensity Physical Activity on Insulin Sensitivity, Mood and Cognitive Performance

Maastricht University Medical Center2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2015年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
24
试验地点
2
主要终点
Plasma insulin levels (measured as area under the curve during an oral glucose tolerance test)

研究概览

简要总结

Background of the study:

A sedentary lifestyle and obesity are well known risk factors of type 2 diabetes. The major focus of current guidelines for type 2 diabetes prevention is on energy balance. Physical activity guidelines recommend at least 30 minutes/day of moderate to vigorous physical activity (MVPA). However, no advice is given how the other 23.5 hours of the day should be spent. Several recent epidemiologic studies suggest that excessive sitting, independent of moderate to vigorous physical activity, has detrimental health effects. Another possibility to sit less is by increasing low intensity physical activities as slowly walking and standing. A recent published study of Duvivier and colleagues suggests that sitting less and replacing it by slowly walking and standing has a better effect on insulin action and cardiovascular risk factors than the combination of one hour MVPA per day and sitting the rest of the day in healthy subjects (Duvivier et al. PLOS ONE 2013). Until now this research is not performed in subjects with overweight/obesity.

Objective of the study:

To assess the effect of low intensity physical activity on plasma insulin levels, cognition and mood in subjects with overweight/obesity

Study population:

21 subjects between 40-80 years old with overweight/obesity

Intervention:

2 activity regimes of 4 days: a sitting regime and a "sit less" regime

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Prevention
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent
  • Men and postmenopausal women: 40-80 years old
  • BMI: 25.0 - 35.0 kg/m2
  • Maximum 2.5 hours of MVPA per week (during last 3 months)
  • Having a general practitioner
  • Agreeing to be informed about medically relevant personal test-results by a physician
  • Accessible veins on arms as determined by examination at screening

排除标准

  • Reported participation in another biomedical trial which may have an effect on insulin sensitivity one month before the pre-study examination or during the study
  • Blood donation in the past three months
  • Reported participation in night shift work 2 weeks prior to pre-study investigation or during the study. Night work is defined as working between midnight and 6.00 AM.
  • Consumption of >14 (women) or > 21 (men) alcoholic units per week
  • Reported dietary habits: medically prescribed diet, slimming diet;
  • Reported weight loss (>2kg) in the last three months prior to the screening;
  • Not being able to execute at least three (out of four) cognition tests in the training session
  • Not being able to execute the sit less try-out day
  • Being an employee of Unilever or the collaborating research departments in Maastricht University Medical Centre
  • Experimental drug use (during the last 3 months)
  • Use of insulin, oral blood glucose lowering medication (metformin and/or SU-derivatives and/or DPP-IV inhibitors), corticosteroids or vitamin K antagonists in the last 3 months
  • Fasting plasma glucose level > 6.9 mmol/L
  • Medical conditions which make participation in the study not responsible which will be decided by a medical doctor during screening
  • Other clinically relevant abnormalities in clinical chemistry at screening (to be judged by a medical doctor)
  • Mental or physical disability which interferes with physical activity

结局指标

主要结局

Plasma insulin levels (measured as area under the curve during an oral glucose tolerance test)

时间窗: one day after each regime

To assess the effect of low intensity physical activity (LIPA) on plasma insulin levels (as measured as area under the curve during an oral glucose tolerance test)

次要结局

  • Plasma total cholesterol(one day after each regime)
  • Plasma C-peptide(one day after each regime)
  • Plasma triglycerides(one day after each regime)
  • Plasma non-HDL cholesterol(one day after each regime)
  • Attention (measured by the Attention Network Task)(one day after each regime before and after the oral glucose tolerance test)
  • Memory (measured by the Rey Auditory Verbal Learning Task)(one day after each regime before and after the oral glucose tolerance test)
  • Plasma interleukin 1(one day after each regime)
  • Insulin sensitivity (measured as Matsuda combined insulin sensitivity index during an oral glucose tolerance test)(one day after each regime)
  • Plasma glucose levels(one day after each regime)
  • Plasma apolipoprotein A(one day after each regime)
  • Mood (measured by the Affect Grid mood scale)(2 days: last day of each regime and one day after each regime)
  • Plasma TNF-alpha(one day after each regime)
  • Plasma interferon gamma(one day after each regime)
  • Plasma E-selectine(one day after each regime)
  • Plasma von Willebrand factor (vWF)(one day after each regime)
  • Blood pressure(one day after each regime)
  • Plasma HDL cholesterol(one day after each regime)
  • Plasma LDL cholesterol(one day after each regime)
  • Plasma free fatty acids(one day after each regime)
  • Plasma apolipoprotein B(one day after each regime)
  • Plasma ICAM-1(one day after each regime)
  • Plasma VCAM(one day after each regime)
  • To explore the association between plasma glucose, plasma insulin, insulin sensitivity and mood, cognitive performance, quality of life and sleep(one day after each regime)
  • Executive Function (measured by the Trail Making Test)(one day after each regime before and after the oral glucose tolerance test)
  • Quality of life (measured by the Gill 32-item questionnaire)(last day of each regime)
  • Sleep (measured by the 10-item Pittsburgh Sleep Quality Index)(last day of each regime)
  • Plasma C-reactive protein(one day after each regime)
  • Plasma serum amyloid A (SAA)(one day after each regime)
  • Plasma PAI-1(one day after each regime)
  • Plasma interleukin 6(one day after each regime)
  • Heart rate(one day after each regime)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验